Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFEI6T)

Drug Name

IPH5201 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SRF617	DMTK1BV	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
TTX-030	DM8H2AG	Lymphoma	2A80-2A86	Phase 1	[3]
PSB-0963	DMBDVJ1	Discovery agent	N.A.	Investigative	[4]
PSB-6426	DMJ9ML8	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)	TTYM8DJ	ENTP1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04261075) IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Surface oncology.
3	Clinical pipeline report, company report or official report of AbbVie.
4	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
5	Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide. J Med Chem. 2008 Aug 14;51(15):4518-28.